BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29125554)

  • 1. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
    Xu Y; Wang Q; Han Y; Song G; Xu X
    J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
    Guan J; Bywaters SM; Brendle SA; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29211035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
    Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
    Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.
    Bywaters SM; Brendle SA; Biryukov J; Wang JW; Walston J; Milici J; Roden RB; Meyers C; Christensen ND
    Virology; 2018 Nov; 524():106-113. PubMed ID: 30170240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
    Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
    J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
    Culp TD; Spatz CM; Reed CA; Christensen ND
    Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.